Begin main content

Pharmaceutical Reviews Update 4

December 13, 2018
See Pharmaceutical Reviews Update – Issue 4 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: an upcoming webinar on the CADTH/pCODR clinician input and feedback process an update on the transition of the Cancer Drug Implementation Advisory Committee work a reminder about pre-submissio...

Call for Feedback: Triple csDMARDs for Rheumatoid Arthritis

December 12, 2018
A document related to the project entitled Triple csDMARDs for Rheumatoid Arthritis is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Triple csDMARDs for Rheumatoid Arthritis 2018-12-12 2019-01-04 Consultation Document Product Type Submit Stakeholder Feedback Proposed Project Scope Optimal ...

Call for Feedback: Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration

December 10, 2018
A document related to the project entitled Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Dual Antiplatelet Therapy Following Percutaneous Coronary In...

New at CADTH - December 2018

December 10, 2018
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Call for Patient Input: filgrastim

November 19, 2018
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website. filgrastim Brand name Generic name Manufacture...